



S6 Fig. Combination effect of BYL719 with afatinib on EBC-1 and capmatinib-resistant cells.

(A) The combination of BYL719 with afatinib showed synergistic growth inhibition only on EBC-CR3. All cells were treated BYL719 with afatinib at 0.1 μmol/L for 72 hrs. (B) The combination of BYL719 with afatinib incompletely inhibited AKT phosphorylation on EBC-1 and -CR2 cells. Cells were treated with afatinib 500 nmol/L, BYL719 1 μmol/L, or BYL719 1 μmol/L with afatinib 500 nmol/L, respectively, for 24 hrs.